Oral Wegovy Pill Shows Strong Response in Recent Weight Gain; Mouse Study Reveals Neuronal 'Memory' Behind Allergies

By Nancy Lapid — This report summarizes two recent studies: a real-world analysis of the oral formulation of Wegovy for people with recent weight gain and a laboratory study in mice that sheds light on how repeated allergen exposures can amplify and broaden allergic sensitivity.

Oral Wegovy May Work Best For People Who Gained Weight Recently

An early real-world analysis of prescription records suggests the oral form of Novo Nordisk's Wegovy could be particularly effective for people who gained weight in the recent past. Investigators reviewed data from 3,011 patients who filled a prescription for oral Wegovy and had a recorded follow-up weight within 180 days.

The researchers defined "super-responders" as patients who lost more than 10% of their baseline body weight during treatment. They found that patients whose weight gain occurred within the last few years were far more likely to become super-responders than those whose weight-gain trajectories extended further back in time. None of the patients in this analysis had previously used other GLP‑1 medicines.

Oral Wegovy received U.S. approval in December of last year. According to the posted report (not yet peer-reviewed), super-responders started treatment lighter on average than non-responders (207 lbs vs. 224.2 lbs; 94.1 kg vs. 101.7 kg). Super-responders were also more likely to have escalated their dose above the 1.5 mg starting dose by day 60. As patients continued therapy, reductions in blood pressure were observed and tracked closely with the amount of weight lost.

"It doesn't matter if you're a 30-year-old who recently in the last five years gained significant weight, or you're a 60-year-old or a 90-year-old that in the last five years gained significant weight, you're far more likely within months to reverse those five years of body weight gain," said study leader Venky Soundararajan of data analytics firm nference.

The authors emphasize that these are observational findings and do not establish cause and effect. They call for prospective, controlled studies to test whether pre-treatment weight trajectory truly predicts response to GLP-1 therapy.

Repeated Exposures May Make Allergies Worse — Mouse Study

A separate study in mice, published in the journal Immunity, investigates why allergies often appear only after repeated exposures and why people with one allergy frequently develop others. The research points to a surprising property of sensory neurons — the nerve cells that relay itch, pain and other sensations to the central nervous system.

Earlier work from the team showed sensory neurons can directly sense certain allergens and help initiate allergic immune responses. The new experiments reveal these neurons retain a metabolically encoded record of prior allergen encounters that primes them to respond more strongly on later exposures, even after the original allergen is no longer present.

Study leader Dr. Caroline Sokol of Mass General Brigham said this neuronal priming activates a specific signaling pathway that increases responsiveness not only to the same allergen but also to other allergens that share similar enzymatic activity despite different molecular structures. This cross‑allergen priming may help explain the progression from one sensitivity to multiple allergies.

The investigators suggest these findings could guide development of interventions to prevent progressive allergic sensitization, though translation from mice to humans will require further research.

Bottom line: A large early real-world analysis suggests oral Wegovy may produce substantial short-term weight loss for people with recent weight gain, while laboratory work in mice identifies a neuronal memory mechanism that could explain how repeated and related exposures worsen allergic disease. Both findings are promising but call for additional, more rigorous studies.